Prepared by:
Duke Evidence-based Practice Center
Durham, NC
David B. Matchar, M.D.
Principal Investigator
Evan R. Myers, M.D., M.P.H.
Matthew W. Barber, M.D.
Grace M. Couchman, M.D.
Santanu Datta, M.B.A., M.S.
Rebecca N. Gray, D.Phil.
Tara Gustilo-Ashby, M.D.
Jane T. Kolimaga, M.S.
Douglas C. McCrory, M.D., M.H.Sc.
File Name Description Software Version File Size __________________________________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 97 SR-1 34KB 8 pages Contents: Title Page, Preface, Abstract, Table of Contents (Volumes 1 and 2) __________________________________________________________________________________________________________ 02summ.doc Microsoft Word® Document MS Word® 97 SR-1 66KB 10 pages Contents: Summary: Overview, Reporting the Evidence, Methodology, Findings, Future Research __________________________________________________________________________________________________________ 03chap1.doc Microsoft Word® Document MS Word® 97 SR-1 99KB 10 pages Contents: Chapter 1. Introduction: Background, Scope and Purpose, Prevalence and Incidence of Uterine Fibroids, Biology of Fibroids, Burden of Illness, Patient Populations, Practice Settings, Target Audiences __________________________________________________________________________________________________________ 04chap2.doc Microsoft Word® Document MS Word® 97 SR-1 172KB 28 pages Contents: Chapter 2. Methodology: Topic Assessment and Refinement, Literature Search and Selection, Data Abstraction, Quality Scoring, Quality Control Procedures, Supplemental Data Sources, Data Synthesis __________________________________________________________________________________________________________ 05chap3.doc Microsoft Word® Document MS Word® 97 SR-1 1.1MB 78 pages Contents: Chapter 3. Results: Question 1. What are the risks and benefits of hysterectomy and myomectomy in the treatment of symptomatic and asymptomatic fibroids? Question 2. What are the risks associated with single versus multiple myomectomies? Question 3. Who are appropriate candidates for each procedure? Question 4. What is the incidence of need for additional treatment after myomectomy or other uterus-sparing interventions? Question 5. Does additional treatment result in significantly increased morbidity? Question 6. What are the risks and benefits of nonsurgical treatment? Question 7. What are the costs associated with effective surgical and nonsurgical treatments? Question 8. Do risks and benefits differ for women according to race, ethnicity, age, interest in future childbearing, and so forth? Question 9. What are the effects of surgical management of uterine fibroids, especially hysterectomy, on the aging process? __________________________________________________________________________________________________________ 06chap4.doc Microsoft Word® Document MS Word® 97 SR-1 251KB 14 pages Contents: Chapter 4. Decision Model: Approach, Clinical Scenario, Methods, Results, Methodological Issues, Summary __________________________________________________________________________________________________________ 07chap5.doc Microsoft Word® Document MS Word® 97 SR-1 58KB 8 pages Contents: Chapter 5. Conclusions: Research Implications, Limitations of the Current Literature, Limitations of the Report, Suggested Strategies for Using This Report __________________________________________________________________________________________________________ 08chap6.doc Microsoft Word® Document MS Word® 97 SR-1 41KB 4 pages Contents: Chapter 6. Future Research: Improving Comparability Across Studies, Improving Knowledge About the Effectiveness of Medical Therapies, Improving Knowledge About Long-Term Outcomes, Improving Knowledge About Basic Epidemiology and Use of Health Services, Improving Knowledge About the Economics of Fibroids __________________________________________________________________________________________________________ 09abbr.doc Microsoft Word® Document MS Word® 97 SR-1 30KB 4 pages Contents: Abbreviations and Acronyms Used in This Report __________________________________________________________________________________________________________ 10refs.doc Microsoft Word® Document MS Word® 97 SR-1 148KB 18 pages Contents: References __________________________________________________________________________________________________________ 11v2covr.doc Microsoft Word® Document MS Word® 97 SR-1 24KB 4 pages Contents: Volume 2 title page and table of contents __________________________________________________________________________________________________________ 12etbl1.doc Microsoft Word® Document MS Word® 97 SR-1 536KB 130 pages Contents: Evidence Table 1. Invasive treatment of uterine fibroids __________________________________________________________________________________________________________ 13etbl2.doc Microsoft Word® Document MS Word® 97 SR-1 278KB 60 pages Contents: Evidence Table 2. Medical management of uterine fibroids __________________________________________________________________________________________________________ 14etbl3.doc Microsoft Word® Document MS Word® 97 SR-1 219KB 38 pages Contents: Evidence Table 3. Preoperative gonadotropin-releasing hormone (GnRH) agonists __________________________________________________________________________________________________________ 15biblio.doc Microsoft Word® Document MS Word® 97 SR-1 172KB 36 pages Contents: Bibliography __________________________________________________________________________________________________________
AHRQ Publication No. 01-E052
Current as of July 2001
Internet Citation:
Management of Uterine Fibroids. File Inventory, Evidence Report/Technology Assessment Number 34. AHRQ Publication No. 01-E052, July 2001. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/utfinv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services